drugset / Trial / NCT00056238
Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy
Phase 2
Completed
30 enrolled
Bellus Health Inc. - a GSK company
National Institute of Neurological Disorders and Stroke (NINDS) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The main objective of this study is to evaluate the safety, tolerability and pharmacokinetics of Cerebril™ in Cerebral Amyloid Angiopathy (CAA) patients who have had lobar cerebral hemorrhage.
Timeline
- Start
- 2003-02
- Primary completion
- —
- Completion
- —
Publications
- Background Gervais F, Chalifour R, Garceau D, Kong X, Laurin J, Mclaughlin R, Morissette C, Paquette J. Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid. 2001 Jul;8 Suppl 1:28-35.
- Background M.C. Belanger, P. Krzywkowski, J. Paquette, M. Yu, C. Ramassamy, P. Tremblay, and F. Gervais. Development of Cerebral Amyloid Angiopathy in the TgCRND8 Mouse Model of Alzheimer's Disease. Data presented at the Society for Neuroscience, Orlando, FL, November 2002.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NC-758 | Unknown | — | — |